Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10

Cancer Science

Volumn 99, Issue 2, 2008, Pages 432-440

  Fukukawa, Chikako ^a   Hanaoka, Hirofumi ^b   Nagayama, Satoshi ^a   Tsunoda, Tatsuhiko ^c   Toguchida, Junya ^d   Endo, Keigo ^b   Nakamura, Yusuke ^a   Katagiri, Toyomasa ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; FRIZZLED PROTEIN; FRIZZLED PROTEIN 10; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 92 13; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SYNOVIAL SARCOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FRIZZLED RECEPTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, CONFOCAL; MODELS, ANIMAL; RADIOIMMUNOTHERAPY; RECEPTORS, G-PROTEIN-COUPLED; SARCOMA, SYNOVIAL;

EID: 38949218365     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00701.x     Document Type: Article

References (16)

1. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
2. Baselga J. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 2001; 61 (Suppl 2): 14-21.
3. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
5. Crist WM, Anderson JR, Meza JL et al. Intergroup rhabdomyosarcoma study-IV. results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-102.
6. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19: 292-315.
7. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80: 1020-33.
8. Nagayama S, Katagiri T, Tsunoda T et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA Microarray. Cancer Res 2002; 62: 5859-66.
9. Koike J, Takagi A, Miwa T, Hirai M, Terada M, Katoh M. Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family. Biochem Biophys Res Commun 1999; 262: 39-43.
10. Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene 2005; 24: 6201-12.
11. Arano Y, Fujioka Y, Akizawa H et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999; 59: 128-34.
12. Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694-705.
13. Chen X, Conti PS, Moats R. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res 2004; 64: 8009-14.
14. Chen W, ten Berge D, Brown J et al. Dishevelled 2 recruits β-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 2003; 301: 1391-4.
15. Bryja V, Cajánek L, Grahn A, Schulte G. Inhibition of endocytosis blocks Wnt signaling to β-catenin by promoting disheveled degradation. Acta Physiol 2007; 190: 55-61.
16. 90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185-8.